Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia.
Michael
M
Fink
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016190:Carboplatin / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D002762:Cholecalciferol / Q000627:therapeutic use; D000077143:Docetaxel; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004408:Dysgeusia / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D013280:Stomatitis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D043823:Taxoids / Q000009:adverse effects; D000068878:Trastuzumab; D016896:Treatment Outcome; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D014808:Vitamin D Deficiency / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D014815:Vitamins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D014815:Vitamins; D014807:Vitamin D; D000077143:Docetaxel; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D; D016190:Carboplatin; D000068878:Trastuzumab